Hsa-miR-142-3p miRNA Probe (DIG)

Catalog # MI0006 Size

Applications



Chromogenic *In Situ* Hybridization (FFPE Tissue)

(A) microRNA in situ hybridization analysis of Hsa-miR-142-3p miRNA Probe (DIG) showing positive staining on FFPE human breast cancer, placenta, colon, lymph node, colon cancer and ovarian cancer tissues.
(B) microRNA in situ hybridization analysis of Hsa-miR-142-3p miRNA Probe (DIG) showing negative staining on FFPE human pancreas tissue and the negative controls on FFPE human breast cancer, placenta, colon, lymph node, colon cancer and ovarian cancer tissues in the absence of probe (No Probe) followed by incubation with primary antibody, secondary antibody and detection reagents.

Specification

Product Description	Hsa-miR-142-3p miRNA Probe (DIG) designed from mature human miR-142 sequence.
miRbase ID	MIMAT0000434
Origin	Human
Reactivity	Human
Form	Liquid
Conjugation	Digoxigenin (DIG)
Notice	Use of FFPE miRNA ISH Pretreatment Solution for the pretreatment of formalin-fixed paraffin-embed ded (FFPE) tissue sections is strongly recommended.
Regulation Status	For research use only (RUO)
Supplied Products	10 reactions, 100 uL miRNA probe

Copyright © 2023 Abnova Corporation. All Rights Reserved.

Storage Instruction	Store at 4°C.

Applications

- Chromogenic *In Situ* Hybridization (FFPE Tissue)

  (A) microRNA in situ hybridization analysis of Hsa-miR-142-3p miRNA Probe (DIG) showing positive staining on FFPE human breast cancer, placenta, colon, lymph node, colon cancer and ovarian cancer tissues.
  (B) microRNA in situ hybridization analysis of Hsa-miR-142-3p miRNA Probe (DIG) showing negative staining on FFPE human pancreas tissue and the negative controls on FFPE human breast cancer, placenta, colon, lymph node, colon cancer and ovarian cancer tissues in the absence of probe (No Probe) followed by incubation with primary antibody, secondary antibody and detection reagents.

Copyright © 2023 Abnova Corporation. All Rights Reserved.